Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?

Publisher: Tehran University of Medical Sciences Country of Publication: Iran NLM ID: 101146178 Publication Model: Print Cited Medium: Print ISSN: 1735-1502 (Print) Linking ISSN: 17351502 NLM ISO Abbreviation: Iran J Allergy Asthma Immunol Subsets: MEDLINE

Publication: 2007- : Tehran : Tehran University of Medical Sciences
Original Publication: Tehran, I.R. Iran : Iranian Society of Asthma and Allergy (ISAA) and the Iranian Society of Immunology and Allergy (ISIA), [2000-2006]

Anaphylaxis/*chemically induced ; Angioedema/*chemically induced ; Drug Hypersensitivity/*etiology ; Immunologic Factors/*adverse effects ; Omalizumab/*adverse effects ; Urticaria/*drug therapy; Adult ; Aged ; Anaphylaxis/diagnosis ; Anaphylaxis/drug therapy ; Angioedema/diagnosis ; Angioedema/drug therapy ; Chronic Disease ; Drug Hypersensitivity/diagnosis ; Drug Hypersensitivity/drug therapy ; Female ; Humans ; Male ; Middle Aged ; Time Factors ; Treatment Outcome ; Urticaria/diagnosis

Omalizumab is a recombinant humanized anti-Ig E monoclonal antibody used as the third line treatment of chronic spontaneous urticaria (CSU). We report four patients with severe antihistamine-resistant CSU, who developed angioedema, anaphylaxis and/or flare up of urticaria at different times following omalizumab therapy.

Keywords: Chronic urticaria, Omalizumab, Adverse reaction

0 (Immunologic Factors)
2P471X1Z11 (Omalizumab)

Date Created: 20160322 Date Completed: 20170117 Latest Revision: 20220408

20240829

26996116